Form 4: Black Diamond Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Director Ali Behbahani acquired 7,646 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services as a non-employee director.

Summary

• On March 21, 2025, Ali Behbahani, a director of Black Diamond Therapeutics, acquired 7,646 shares of common stock.
• The shares were issued in lieu of cash compensation for annual services as a non-employee director, according to the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• The price per share was $1.88, based on the closing market price of the Issuer's common stock on March 20, 2025.
• Following the transaction, Mr. Behbahani directly owns 70,980 shares and indirectly owns 4,448,757 shares through NEA 16.
• Mr. Behbahani disclaims beneficial ownership of the securities held by NEA 16 in which he has no pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine director compensation matter. The director taking shares instead of cash is a slightly positive signal.

Positives

• The director's decision to take shares in lieu of cash compensation could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director share acquisitions are common and are usually viewed as a sign of confidence in the company's future. This transaction is related to director compensation policies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Black Diamond Therapeutics, Director, Share Acquisition, Form 4, Compensation, Ali Behbahani, BDTX, NEA 16